Secukinumab Biosimilar - Research Grade

Human

IL17A

>1mg/ml

Human IgG1 Kappa

Humanized

Ixekizumab Biosimilar - Research Grade (ICH5165), Xeligekimab Biosimilar - Research Grade (ICH5289), Afasevikumab Biosimilar - Research Grade (ICH5330), Bimekizumab Biosimilar - Research Grade (ICH5403), Gumokimab Biosimilar - Research Grade (ICH5586), Netakimab Biosimilar - Research Grade (ICH5709), Perakizumab Biosimilar - Research Grade (ICH5769), Roconkibart Biosimilar - Research Grade (ICH5829), Vunakizumab Biosimilar - Research Grade (ICH5995)

https://www.imgt.org/mAb-DB/

ICH3001-100ml ICH3002-100ml ICH3003-100ml

Q16552

3605

RRID:AB_2921548

Blue ice

This product is a research-grade, unconjugated recombinant analog of secukinumab, a fully human IgG1-kappa monoclonal antibody directed against human interleukin-17A (IL-17A, UniProt Q16552). It is a non-therapeutic biosimilar intended strictly for research use only; it is not the clinical drug and is not for human or veterinary use. Reproducing the published antigen specificity and human IgG1-kappa framework of the originator, it is a useful reference reagent for studying IL-17A biology, benchmarking IL-17A-targeting molecules, and serving as an isotype-matched, well-defined positive control in binding and neutralization assays. Because it is offered at research scale, it supports method development, assay standardization, and in-vitro and preclinical workflows where a consistent, well-characterized anti-IL-17A antibody is needed. It is available in bulk quantities (milligram to gram) and in low-endotoxin grades (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) suitable for cell-based and sensitive functional experiments. Format is unconjugated, leaving it open for downstream labeling, immobilization, or engineering. Interleukin-17A (IL-17A) is a pro-inflammatory cytokine and the founding member of the IL-17 family. It is produced chiefly by Th17 CD4+ T cells, but also by CD8+ T cells, gamma-delta T cells, innate lymphoid cells, natural killer cells, and neutrophils. IL-17A is secreted as a disulfide-linked homodimer and can also form heterodimers with IL-17F. It signals through a receptor complex of IL-17RA and IL-17RC, recruiting the adaptor ACT1 to drive NF-kB, MAPK, and C/EBP signaling. This induces expression of pro-inflammatory cytokines, chemokines (including CXCL1, CXCL8/IL-8), antimicrobial peptides, and matrix metalloproteinases from epithelial cells, fibroblasts, and keratinocytes. IL-17A supports host defense against extracellular bacteria and fungi, but its dysregulation is central to autoimmune and inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, making it a validated therapeutic and research target.

Interleukin-17A, IL17A, CTLA-8, CTLA8

Detects human IL17A. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Secukinumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0013

Secukinumab (anti-IL17A) Biosimilar

Q: Is the Secukinumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Secukinumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Secukinumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Secukinumab that binds human IL17A.